(Q36689035)

15 August 2017

1 reference

title

Therapeutic vaccination in chronic hepatitis B virus carriers (English)

1 reference

15 August 2017

1 reference

1 reference

1 reference

1

Stanislas Pol

1 reference

15 August 2017

Marie-Louise Michel

2

1 reference

15 August 2017

1 October 2006

1 reference

Expert Review of Vaccines

15 August 2017

1 reference

15 August 2017

5

1 reference

15 August 2017

707-716

1 reference

15 August 2017

5

1 reference

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

15 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

Resistance of HBV to adefovir dipivoxil: a case for combination antiviral therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

Immunomodulatory drugs and therapeutic vaccine in chronic hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

Hepatitis B virus immunopathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

Immunology of hepatitis B virus and hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

Genomic analysis of the host response to hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

Tumor necrosis factor alpha inhibition of hepatitis B virus replication involves disruption of capsid Integrity through activation of NF-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

The immune response during hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

Kinetics of the immune response during HBV and HCV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

Evidence for a deficiency of interferon production in patients with chronic hepatitis B virus infection acquired in adult life

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

Virus-specific lymphokine production differs quantitatively but not qualitatively in acute and chronic hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

Hepatic interferon-alpha gene transcripts and products in liver specimens from acute and chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

Transplantation of hepatitis B immune lymphocytes as means for adoptive transfer of immunity to hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

Treatment of chronic hepatitis B virus infection via oral immune regulation toward hepatitis B virus proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

NKT cells: facts, functions and fallacies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

Modulation of the immunological response to hepatitis B virus by antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

Immunostimulatory DNA sequences necessary for effective intradermal gene immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

DNA-based immunization against the envelope proteins of the hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

Maternally transferred antibodies from DNA-immunized avians protect offspring against hepadnavirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

Successful nucleic acid based immunization of newborn chimpanzees against hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

DNA prime/canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

Human clinical trials of plasmid DNA vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.707

21 January 2018

Identifiers

DOI

10.1586/14760584.5.5.707

1 reference

15 August 2017

1 reference

PubMed ID

17181443